FDA Clears Ascidian for First-Ever RNA Editing Trial in US

Ascidian Therapeutics has received IND clearance from the FDA and has been granted Fast Track Designation for its asset to treat Stargardt disease, a genetic eye disease that can cause blindness in children and young adults, the company announced Monday.